News
News

The latest updates from AFAR.

AFAR Experts in the News: Nir Barzilai, Jay Olshansky, David Sinclair, and Eric Verdin in The Boston Globe on targeting aging, biotechnology startups, and extending healthspan

Dec 4
2018

AFAR Experts in the News: Nir Barzilai, Jay Olshansky, David Sinclair, and Eric Verdin in The Boston Globe on targeting aging, biotechnology startups, and extending healthspan

On December 1, 2018, The Boston Globe highlighted the insights of AFAR experts Nir  Barzilai, M.D., Jay Olshansky, Ph.D., David Sinclair, Ph.D., and Eric Verdin, Ph.D. on targeting aging, longevity, and extending healthspan. Dr. Barzilai is a 1997 Beeson Scholar, a 1994 AFAR Research Grant recipient, and AFAR’s Deputy Scientific Director. Dr. Olshansky is a 2016 Irving S. Wright Award winner and an AFAR board member. Dr. Sinclair is a 2018 Irving S. Wright Award winner, a 2000 AFAR Research Grant recipient, and an AFAR Board member. Dr. Verdin served on AFAR’s National Scientific Advisory Committee from 2010-2015. …


View MoreREAD MORE


Board Members in the News: Nir Barzilai and David Sinclair in Wired UK’s “The Wired World in 2019” special issue

Nov 29
2018

Board Members in the News: Nir Barzilai and David Sinclair in Wired UK’s “The Wired World in 2019” special issue

  In Fall, 2018, Wired UK published an editorial co-authored by AFAR experts Nir Barzilai, MD and David Sinclair, PhD in its “The Wired World in 2019" special issue, which predicts trends that will shape the year ahead. The AFAR experts co-authored the article, “We will start to treat aging as a disease.” The article spotlight's AFAR's role in managing the TAME Trial. Dr. Barzilai is a 1997 Beeson Scholar, 1994 AFAR Research Grant recipient, and AFAR’s Deputy Scientific Director. Dr. Sinclair is a 2018 Irving S. Wright Award winner, a 2000 AFAR Research Grant recipient, and AFAR…


View MoreREAD MORE


AFAR Experts in the News: NY Times “11 Things We We’d Really Like To Know” features Barzilai, Kirkland, Olshansky, and Sinclair on healthspan, interventions, and more.

Nov 21
2018

AFAR Experts in the News: NY Times “11 Things We We’d Really Like To Know” features Barzilai, Kirkland, Olshansky, and Sinclair on healthspan, interventions, and more.

On November 19, 2018, The New York Times “11 Things We’d Really Like to Know” feature spotlighted AFAR experts Nir Barzilai M.D., James L. Kirkland, M.D., Ph.D., S. Jay Olshansky, Ph.D., and David Sinclair, Ph.D. on lifespan vs. healthspan, promising drug interventions such as senolytics and NAD boosters, and  the Targeting Aging with Metformin Trial. Dr. Barzilai is a 1997 Beeson Scholar and 1994 AFAR Research Grant recipient, and AFAR’s Deputy Scientific Director. Dr. Kirkland is a 2012 Glenn/AFAR Breakthroughs in Gerontology (BIG) Award recipient and AFAR President-elect. Dr. Olshansky is a 2016 Irving…


View MoreREAD MORE


AFAR Experts in the News: Reisa Sperling and Rudy Tanzi in The New York Times on the search for a cure for Alzheimer’s

Nov 21
2018

AFAR Experts in the News: Reisa Sperling and Rudy Tanzi in The New York Times on the search for a cure for Alzheimer’s

On November 19, 2018, The New York Times highlighted the insights of AFAR experts Reisa Sperling, M.D., M.M.Sc., and Rudy Tanzi, Ph.D. on the search for a cure for Alzheimer’s disease. Dr. Sperling is a 2003 Paul B. Beeson Emerging Leaders Career Development Award in Aging scholar.  Dr. Tanzi is an AFAR board member.   Read “Will We Ever Cure Alzheimer’s? here.


View MoreREAD MORE


Board Member in the News: David Sinclair in HBO AXIOS on a molecule that could hold the secret to longevity

Nov 21
2018

Board Member in the News: David Sinclair in HBO AXIOS on a molecule that could hold the secret to longevity

On November 18, 2018, HBO Documentary Films AXIOS documentary series featured AFAR expert David Sinclair Ph.D.  Dr. Sinclair lends insights on a molecule that could extend longevity. Dr. Sinclair is a 2018 Irving S. Wright Award winner, 2000 AFAR Research Grant recipient, and an AFAR Board Member. Learn more about the AXIOS series here and in a related article on Medium.com.


View MoreREAD MORE




BACK TO TOPBACK TO TOP